Biomedical researchers are at their most creative/innovative EARLY in their career. Study based on 5.6 million papers (1980 to 2009). While least innovative drop out early; in the remaining, innovativeness tends to decline over their career.https://t.co/XY5xQfY8Ba https://t.co/Cs3MUr7qIi

Large retrospective claims data analysis of 86 964 adults w/ severe obesity and NAFLD: comparing bariatric surgery (35%) to those with nonsurgical care. Bariatric surgery lowered the risk of CVD by 49% https://t.co/xEVVQVEX30 https://t.co/gSUIeH1K0k

2 HIV+ pts with HLH (MAS) successfully Rx w/ JAKi - ruxolitinib. Both had high fevers, severe pancytopenia, hypofibrinogenemia, hypertriglyceridemia, & increased ferritin, BMBx Hemophagocytosis, splenomegaly. https://t.co/yGs7e4Ftgp https://t.co/cv9NX31bZr

ACR suggests a new ICD-10 code for "Pre-clinical RA".(PROPOSED NEW CODE: R76.81 “Abnormal rheumatoid arthritis-related immunologic findings without current or prior diagnosis of clinically apparent inflammatory arthritis.” This is not yet final. https://t.co/2Td0lYiUKg https://t.co/8m2OSfPWXz

Single center use IL-23 inhibitors (Guselkumab, Tildrakizumab, Risankizumab) in 80 PsA pts shows 1 yr survival 81%, w/ mean survival 61 wks (despite 95% Rx ≥1 prior biologics). 64% had PASI ≤2 at wks 12-17 and nearly 41% w/ PsA remission https://t.co/woDXhL44d5 https://t.co/6fvjzGlMEY

Record a Question or Comment... Rheums: Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/rICbSJzPbk https://t.co/VIjlR6xlwQ

Tofacitinib shows promise in scleroderma https://t.co/6qUGLlztBd https://t.co/Mk2x2HAkiO

Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow. https://t.co/EGXslouPmC https://t.co/UVcdjzbxYp

Tofacitinib in 15 pts w/ early diffuse skin Scleroderma. Tofa downregulated STAT3 (macrophages, DCs) & IFN (fibroblasts) & MYOC/CCL19 (adventitial fibroblasts); well tolerated & trend to improved mRSS scores (ns) https://t.co/givh5j3m9z https://t.co/ms97tvQy5e

Comprehensive full-read review of #Baricitinib trials in treating COVID-19. 24 studies (16 retrospective, 5 prospective, 3 case control) studies & 3 larged RCTs show Bari as 24-38% better than comparators/SOC (few showed no change in mortality) https://t.co/2svMMX4wDw https://t.co/zoSGGZJYui

8 pts w/ Refractory Skin Dermatomyositis Rx w/ open label APREMILAST, @ 3 mos 7/8 pts responded w/ drop in CDASI (-12.9 pts; P < .001). Skin Bx showed downregulation of multiple inflamm pathways (STAT1/3, IL-4), IL-6, IL-12, IL-23, IFNγ & TNFα) https://t.co/mLElrRgFF1 https://t.co/4eidnPYdXJ

Transitioning JIA to Adult Care is Problematic Juvenile idiopathic arthritis (JIA) may start in adolescence and extend into adulthood. This report shows that rheums need to develop "transition" practices to avoid a gap in healthcare. https://t.co/DV8BZjcP5e https://t.co/e1rFXWSmXN